217 related articles for article (PubMed ID: 9686723)
1. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
O'Shea TM; Sevick MA; Givner LB
Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
[TBL] [Abstract][Full Text] [Related]
3. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
Pediatrics; 1997 Jan; 99(1):93-9. PubMed ID: 8989345
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.
Pediatrics; 1997 Apr; 99(4):645-50. PubMed ID: 9093323
[TBL] [Abstract][Full Text] [Related]
8. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk.
Rietveld E; De Jonge HC; Polder JJ; Vergouwe Y; Veeze HJ; Moll HA; Steyerberg EW
Pediatr Infect Dis J; 2004 Jun; 23(6):523-9. PubMed ID: 15194833
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus immune globulin: decisions and costs.
Barton LL; Grant KL; Lemen RJ
Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
[TBL] [Abstract][Full Text] [Related]
10. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
11. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
13. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
16. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
[TBL] [Abstract][Full Text] [Related]
17. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.
Shi N; Palmer L; Chu BC; Katkin JP; Hall CB; Masaquel AS; Mahadevia PJ
J Med Econ; 2011; 14(3):335-40. PubMed ID: 21524154
[TBL] [Abstract][Full Text] [Related]
18. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
20. A cost-benefit analysis of RSV prophylaxis in high-risk infants.
Schrand LM; Elliott JM; Ross MB; Bell EF; Mutnick AH
Ann Pharmacother; 2001 Oct; 35(10):1186-93. PubMed ID: 11675842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
